GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (NAS:VIRX) » Definitions » Additional Paid-In Capital

VIRX (Viracta Therapeutics) Additional Paid-In Capital : $288.83 Mil(As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Additional Paid-In Capital?


Viracta Therapeutics's quarterly additional paid-in capital increased from Mar. 2024 ($280.70 Mil) to Jun. 2024 ($282.12 Mil) and increased from Jun. 2024 ($282.12 Mil) to Sep. 2024 ($288.83 Mil).

Viracta Therapeutics's annual additional paid-in capital increased from Dec. 2021 ($254.59 Mil) to Dec. 2022 ($270.70 Mil) and increased from Dec. 2022 ($270.70 Mil) to Dec. 2023 ($278.79 Mil).


Viracta Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Viracta Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Additional Paid-In Capital Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
4.71 254.59 270.70 278.79

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 276.78 278.79 280.70 282.12 288.83

Viracta Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Viracta Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Viracta Therapeutics Business Description

Traded in Other Exchanges
Address
2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Executives
Daniel R. Chevallard officer: Chief Executive Officer C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Mark Rothera director, officer: President and CEO C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Darrel P. Cohen officer: Chief Medical Officer C/O VIRACTA THERAPEUTICS, INC., 2533 S. COAST HWY 101, SUITE 210, CARDIFF CA 92007
Lisa Rojkjaer officer: Chief Medical Officer C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007
Ivor Royston director, officer: CEO & President 4401 WILSHIRE BLVD., SUITE 200, LOS ANGELES CA 90010
Jane Chung director C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Flavia Borellini director C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barry J. Simon director 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Stephen Rubino director C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007
Gur Roshwalb director, 10 percent owner C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael Huang director C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Amoon Growth Fund Limited Partnership 10 percent owner 34 YERUSHALAYIM RD., RAANANA L3 4350110
Thomas E Darcy director C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121